Amgen Inc. (AMGN)
Healthcare • Drug Manufacturers - General
StockNasdaqGSUnited StatesUS0311621009
467.06 USD
-0.22% today Updated 12 Nov 2026 21:00
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Amgen Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 12 Nov 2026 21:00. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Next results
02 Feb 2027
in 81 days · 16:00 · estimate 5.64
Last results
6.45 vs 5.78 estimated
03 Nov 2026 · Beat +11.6%
Beat the estimate
11 of 12
0 missed · 1 in line · 9 beats in a row
Average surprise
+8.6%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 02 Feb 2027 16:00 | 5.64 | — | — | Upcoming |
| 03 Nov 2026 16:00 | 5.78 | 6.45 | +11.6% | Beat |
| 04 Aug 2026 16:00 | 5.62 | 6.29 | +12.0% | Beat |
| 30 Apr 2026 16:00 | 4.77 | 5.15 | +8.0% | Beat |
| 03 Feb 2026 16:00 | 4.73 | 5.29 | +11.9% | Beat |
| 04 Nov 2025 16:00 | 5.01 | 5.64 | +12.5% | Beat |
| 05 Aug 2025 16:00 | 5.28 | 6.02 | +14.1% | Beat |
| 01 May 2025 16:00 | 4.26 | 4.90 | +15.0% | Beat |
| 04 Feb 2025 16:00 | 5.08 | 5.31 | +4.6% | Beat |
| 30 Oct 2024 16:00 | 5.11 | 5.58 | +9.3% | Beat |
| 06 Aug 2024 16:00 | 5.00 | 4.97 | -0.6% | In line |
| 02 May 2024 16:00 | 3.89 | 3.96 | +1.8% | Beat |
| 06 Feb 2024 16:00 | 4.59 | 4.71 | +2.6% | Beat |
| 31 Oct 2023 07:00 | 4.68 | 4.96 | +5.9% | Beat |
| 03 Aug 2023 16:00 | 4.49 | 5.00 | +11.3% | Beat |
| 27 Apr 2023 16:00 | 3.85 | 3.98 | +3.3% | Beat |
| 31 Jan 2023 16:00 | 4.09 | 4.09 | 0.0% | In line |
| 03 Nov 2022 16:00 | 4.45 | 4.70 | +5.6% | Beat |
| 04 Aug 2022 16:00 | 4.33 | 4.65 | +7.3% | Beat |
| 27 Apr 2022 12:00 | 4.12 | 4.25 | +3.1% | Beat |
| 07 Feb 2022 16:00 | 4.04 | 4.36 | +8.0% | Beat |
| 02 Nov 2021 16:00 | 4.22 | 4.67 | +10.7% | Beat |
| 03 Aug 2021 16:00 | 4.01 | 4.38 | +9.2% | Beat |
| 27 Apr 2021 16:00 | 4.04 | 3.70 | -8.5% | Miss |
| 02 Feb 2021 16:00 | 3.35 | 3.81 | +13.9% | Beat |
| 28 Oct 2020 16:00 | 3.75 | 4.37 | +16.4% | Beat |
| 28 Jul 2020 16:00 | 3.77 | 4.25 | +12.8% | Beat |
| 30 Apr 2020 17:00 | 3.75 | 4.17 | +11.3% | Beat |
| 30 Jan 2020 16:00 | 3.42 | 3.64 | +6.5% | Beat |
| 29 Oct 2019 16:00 | 3.53 | 3.66 | +3.6% | Beat |
| 30 Jul 2019 16:00 | 3.58 | 3.97 | +10.8% | Beat |
| 30 Apr 2019 16:00 | 3.48 | 3.56 | +2.3% | Beat |
| 29 Jan 2019 16:00 | 3.27 | 3.42 | +4.5% | Beat |
| 30 Oct 2018 16:00 | 3.45 | 3.69 | +6.8% | Beat |
| 26 Jul 2018 16:00 | 3.56 | 3.83 | +7.7% | Beat |
| 24 Apr 2018 16:00 | 3.25 | 3.47 | +6.9% | Beat |
| 01 Feb 2018 16:00 | 3.03 | 2.89 | -4.7% | Miss |
| 25 Oct 2017 16:00 | 3.10 | 3.27 | +5.3% | Beat |
| 25 Jul 2017 16:00 | 3.11 | 3.27 | +5.2% | Beat |
| 26 Apr 2017 16:00 | 3.01 | 3.15 | +4.8% | Beat |
| 02 Feb 2017 16:00 | 2.79 | 2.89 | +3.7% | Beat |
| 27 Oct 2016 16:00 | 2.80 | 3.02 | +8.0% | Beat |
| 27 Jul 2016 16:00 | 2.74 | 2.84 | +3.7% | Beat |
| 28 Apr 2016 16:00 | 2.61 | 2.90 | +11.3% | Beat |
| 28 Jan 2016 16:00 | 2.28 | 2.61 | +14.3% | Beat |
| 28 Oct 2015 16:00 | 2.37 | 2.72 | +14.8% | Beat |
| 30 Jul 2015 16:00 | 2.42 | 2.57 | +6.0% | Beat |
| 21 Apr 2015 16:00 | 2.11 | 2.48 | +17.7% | Beat |
| 27 Jan 2015 16:00 | 2.05 | 2.16 | +5.4% | Beat |
| 27 Oct 2014 16:00 | 2.12 | 2.30 | +8.7% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 36.8B | +10.0% | 7.7B | 21.0% | 14.23 | +88.2% | 8.1B |
| 2024 | 33.4B | +18.6% | 4.1B | 12.2% | 7.56 | -39.5% | 10.4B |
| 2023 | 28.2B | +7.1% | 6.7B | 23.8% | 12.49 | +3.1% | 7.4B |
| 2022 | 26.3B | — | 6.6B | 24.9% | 12.11 | — | 8.8B |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 12 Nov 2026 | 471.86 | 474.00 | 466.92 | 467.06 | -0.22% | 1,271,351 | |
| 11 Nov 2026 | 460.98 | 468.46 | 459.14 | 468.11 | +0.62% | 2,004,900 | |
| 10 Nov 2026 | 465.70 | 468.80 | 459.45 | 465.23 | 0.00% | 2,138,900 | |
| 09 Nov 2026 | 465.14 | 466.54 | 454.46 | 465.23 | +1.04% | 2,310,700 | |
| 06 Nov 2026 | 448.17 | 462.91 | 447.04 | 460.42 | +0.03% | 2,579,400 | |
| 05 Nov 2026 | 483.99 | 483.99 | 459.65 | 460.28 | -3.80% | 4,105,800 | |
| 04 Nov 2026 | 479.61 | 482.48 | 464.13 | 478.48 | +3.73% | 4,618,500 | |
| 03 Nov 2026 | 463.38 | 467.04 | 460.15 | 461.26 | -0.90% | 2,382,000 | |
| 02 Nov 2026 | 463.43 | 469.00 | 461.00 | 465.45 | -0.12% | 3,192,900 | |
| 30 Oct 2026 | 470.15 | 475.65 | 465.33 | 466.01 | +1.15% | 3,290,400 | |
| 1,254 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Is Amgen Stock Priced Right Against Its Peers? (opens in a new tab) Trefis · 12 Nov 2026 19:15
- Amgen’s acquired Sjögren’s drug a Phase III hit (opens in a new tab) Clinical Trials Arena · 12 Nov 2026 11:52
- 45 ETFs Add to Amgen (AMGN) Holdings on Tuesday (opens in a new tab) GuruFocus.com · 12 Nov 2026 11:02
- Argus Research Maintains Buy on Amgen, Raises Price Target to $515 (opens in a new tab) Benzinga · 12 Nov 2026 09:46
- Amgen, In A Buy Zone, Unveils Highly Anticipated Novartis-Rivaling Sjogren's Data (opens in a new tab) Investor's Business Daily · 11 Nov 2026 21:02
- Amgen (AMGN) Stock Looks Cheap Based On Future Cash Flow (opens in a new tab) Simply Wall St. · 11 Nov 2026 16:10
- Amgen Reports Phase 3 Dazodalibep Trial Meets Primary Endpoint in Sjögren’s Disease (opens in a new tab) InvestorsHub · 11 Nov 2026 15:24
- Gene Therapy - Global Strategic Business Report: Capitalize on 23% CAGR as the Market Hits US$6 Billion by 2030; Benchmark Amgen, Alnylam, BioMarin, Biogen and bluebird bio (opens in a new tab) 11 Nov 2026 14:10
- AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE (opens in a new tab) 11 Nov 2026 13:00
- Amgen Experimental Drug Shows Symptom Reductions in Chronic Autoimmune Disease That Impacts Tears (opens in a new tab) Benzinga · 11 Nov 2026 11:06
- iShares Biotechnology ETF (IBB) Adds Gilead and Amgen on Nov. 9 (opens in a new tab) GuruFocus.com · 11 Nov 2026 11:04
- Amgen Says Dazodalibep Met Primary Endpoint At Week 48 (opens in a new tab) Benzinga · 11 Nov 2026 09:01
- Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later? (opens in a new tab) 24/7 Wall St. · 10 Nov 2026 18:17
- Explosive Options' Bob Lang on why he likes Amgen (opens in a new tab) CNBC · 10 Nov 2026 14:52
- Amgen’s Repatha shows cost-effectiveness in cardiovascular study (opens in a new tab) TipRanks · 10 Nov 2026 05:05
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 468.11 USD
- Market cap
- 253.2B
- Dividend yield
- 2.15%
- 5-year average yield
- 2.98%
- Payout ratio
- 58%
- Last dividend
- 2.5200 USD · 20 Nov 2026
- Next ex-dividend date
- 20 Nov 2026
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Currency
- USD
Dividends
| Ex-dividend date | Per share |
|---|---|
| 21 Aug 2026 | 2.5200 USD |
| 15 May 2026 | 2.5200 USD |
| 13 Feb 2026 | 2.5200 USD |
| 21 Nov 2025 | 2.3800 USD |
| 8 older dividends: create a free account to see them | |
Why this score
Similar shares
Follow AMGN and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.